

Methodological Notes

Disclosure by Fresenius Kabi (Schweiz) AG of payments to Swiss healthcare professionals and healthcare organizations in 2025

The Code of Conduct of the Pharmaceutical Industry in Switzerland (Pharma Code PC) on cooperation with healthcare professionals, healthcare organizations and patient organizations (Pharma Cooperation Code) mandates the public disclosure of transfers of value made during 2025 to Swiss healthcare professionals and healthcare organizations. The disclosure data will be published on the website Fresenius Kabi (Schweiz) AG, [Fresenius Kabi Switzerland](#).

The disclosure requirements are set forth in Section 2 of the Pharma Cooperation Code. The methodological notes below explain the data Fresenius Kabi (Schweiz) AG have disclosed and how the data have been prepared, to assist the reader's understanding.

VAT

VAT is excluded from all disclosures of transfer of value.

Currency

All disclosures are made in Swiss Francs (CHF). Where the original payment was made in Euros, the sum was converted to Swiss Francs at the average exchange rate of the month of payment published in June 2025.

Performance identification and recognition

All disclosed payments are based on the monetary benefits actually paid in the relevant category, provided that such a monetary benefit was directed to a specific recipient and recognized in the reporting period concerned.

Multi-year contracts

Monetary benefits under multi-year contracts are part of the disclosed data to the extent that monetary benefits were actually paid in the reporting period in question.

Data Protection

Consent to disclose

In countries where it is required by applicable data protection laws, Fresenius Kabi (Schweiz) AG has taken all reasonable steps to obtain consents from the HCPs, and HCOs, as applicable, to publicly disclose payments and other transfers of value. If consent is not provided, the data will be reported on an aggregate level only.

Consent collection and withdrawal

Fresenius Kabi (Schweiz) AG respects applicable data protection laws. If a stakeholder withdraws the provided consent, Fresenius Kabi (Schweiz) AG will adjust the publication accordingly within a reasonable time.

Data included

The data disclosed by Fresenius Kabi (Schweiz) AG is going beyond the requirements of the Pharma Cooperation Code, as it not only covers payments to Swiss HCPs and HCOs in relation to prescription drugs, but also in our Medical Device and Clinical Nutrition business.

All Transfers of Value made by any Fresenius Kabi legal entity (incl. cross-border payments) are included for Healthcare professionals or healthcare organizations with a primary practice or relevant business address or registered office in Switzerland.

Data is included, if the actual payment date was between January 1st and December 31st 2025.

The data can be categorized as follows:

Contribution to costs of Events

Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event

Disclosed data includes payments to healthcare organizations that represent a contribution of costs related to an event. Such data includes the following types of payments paid to the healthcare organizations or via a third party appointed by the healthcare organization to organize an event: fees for exhibition/booth space at an event; fees for event exhibition badges and event registration fees; fees related to advertising at an event; and sponsorship fees related to an event or satellite symposium at an event.

Financial support for healthcare professionals attending events for further education or advanced training

Disclosed data includes the payment to support Swiss healthcare professionals in 2025 who attended events for further education or advanced training. Where applicable, the disclosure data also includes payment of reasonable expenses to such healthcare professionals, such as travel expenses and/or accommodation expenses.

Payment of consultants who provide services to Fresenius Kabi (Schweiz) AG

Disclosed data includes the payment of honoraria to Swiss healthcare professionals in 2025 who provided services to Fresenius Kabi (Schweiz) AG. Where applicable, the disclosure data also includes payment of reasonable expenses to such consultants incurred in the delivery of their services, such as travel expenses and/or accommodation expenses.

Cooperation with healthcare professionals, healthcare organizations and patient organizations

Disclosed data includes the payment for service contracts with Swiss healthcare organizations in 2025 in support of healthcare, research and development with a justified need.